Solid Biosciences (SLDB) Current Assets (2017 - 2026)

Solid Biosciences has reported Current Assets for 10 years, with the latest figure at $396.8 million in Q1 2026.

• Quarterly Current Assets rose 26.6% year-over-year to $396.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $396.8 million (up 26.6% YoY) and the FY2025 annual result came in at $205.5 million, up 30.61% from the prior year.
• Current Assets climbed to $396.8 million in Q1 2026 per SLDB's latest filing, from $205.5 million in the prior quarter.
• Over five years, Current Assets peaked at $396.8 million in Q1 2026 and troughed at $129.7 million in Q4 2023.
• A 5-year average of $209.4 million and a median of $197.6 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2025: Current Assets sank 40.93% in 2023, then jumped 46.32% in 2025.
• Over 5 years, Current Assets stood at $219.6 million in 2022, then tumbled by 40.93% to $129.7 million in 2023, then grew by 21.25% to $157.3 million in 2024, then soared by 30.61% to $205.5 million in 2025, then soared by 93.13% to $396.8 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $396.8 million, $205.5 million, and $244.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.